Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.

Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting.

<h4>Introduction</h4>Chronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise.<h4>Materials and methods<...

Full description

Bibliographic Details
Main Authors: Hsu-Heng Yen, Pei-Yuan Su, Ya-Huei Zeng, I-Ling Liu, Siou-Ping Huang, Yu-Chun Hsu, Yang-Yuan Chen, Chia-Wei Yang, Shun-Sheng Wu, Kun-Ching Chou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0237582

Internet

https://doi.org/10.1371/journal.pone.0237582

Similar Items